NCT00523432View on ClinicalTrials.gov

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

December 31, 2010

Conditions
Genital Neoplasms, Female
Interventions
DRUG

Topotecan

Weekly doses via IV infusion. Dose will be assigned based on time of study entry.

DRUG

CCI-779 (temsirolimus)

Weekly 25mg dose via IV infusion.

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

University of Chicago

OTHER

NCT00523432 - A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies | Biotech Hunter | Biotech Hunter